Skip to content

The effect of Chlorella Volgaris versus Arthichoke on patients with NAFLD- A randomized clinical trial

The effect of Chlorella Volgaris versus Arthichoke on patients with NAFLD- A randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014101619554N1
Enrollment
200
Registered
2015-04-02
Start date
2014-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. nonalcoholic steatohepatitis

Interventions

Intervention 1: Intervention:30 patient as the control group only received treatment with metformin and vitamin E, The second group,30 patients were treated with Chlorella supplements and third group
Treatment - Drugs
In the control group, 30 patients receiving metformin 500 mg( is made of Eksir company) 2 times a day, after breakfast and dinner,also vitamin E 400 IU ( is made of Eksir company)once a day after lunc
Intervention:30 patient as the control group only received treatment with metformin and vitamin E, The second group,30 patients were treated with Chlorella supplements and third group (30 patients),we

Sponsors

Vice Chancellor for Research,Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Inclusion criteria: Proven fatty liver by Ultrasound, Increase liver enzyme alanine aminotransferase (ALT) between 1.5 to 5 times the normal; The mean BMI between 25-35 Exclusion criteria: Patients with nonalcoholic steatohepatitis; Patients with systemic diseases such as diabetes - and other inflammatory diseases; Positive serology for hepatitis viral, anti-mitochondrial antibody (AMA); positive anti- nuclear antibody (ANA); TIBC increased serum iron and transferrin,TIBC, positive serum ceruloplasmin; Other secondary causes of fatty liver, Transferrin saturation more than 45.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Liver Function Test. Timepoint: 2m after intervention. Method of measurement: Eliza method.

Secondary

MeasureTime frame
BMI(Body Mass Index). Timepoint: 2m. Method of measurement: kg/m2.;Blood Presser. Timepoint: 2m. Method of measurement: Digital manometer.;Lipid Profil. Timepoint: 2month. Method of measurement: Eliza.;Blood sugar. Timepoint: 2month. Method of measurement: Eliza.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVice Chancellor for Research,Zanjan University of Medical Sciences,.Dr Faghihzade Soghrat

Zanjan University of Medical Sciences,

Dr.shirinjameshorani@yahoo.com ; Dr.shirinjameshorani@zums.ac.ir+98 24 3377 0805

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026